![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » DE NOVO PHARMACEUTICALS ANNOUNCES NEW THERAPEUTIC FOCUS IN THE AREA OF METABOLIC DISEASES
DE NOVO PHARMACEUTICALS ANNOUNCES NEW THERAPEUTIC FOCUS IN THE AREA OF METABOLIC DISEASES
May 9, 2006
De Novo Pharmaceuticals Ltd., a world leader in computational drug design, has announced that it is expanding its drug design business to establish a new therapeutic focus in the area of metabolic diseases. To help support this and strengthen the Company's scientific base, it has appointed a new Scientific Advisory Board.
Yahoo News (http://biz.yahoo.com/prnews/060509/ukm006.html?.v=57)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct